CLINICAL TRIALS AND OBSERVATIONS Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group
نویسندگان
چکیده
Heinz Ludwig,1 Brian G. M. Durie,2 Vanessa Bolejack,3 Ingemar Turesson,4 Robert A. Kyle,5 Joan Blade,6 Rafael Fonseca,7 Meletios Dimopoulos,8 Kazuyuki Shimizu,9 Jesus San Miguel,10 Jan Westin,11 Jean-Luc Harousseau,12 Meral Beksac,13 Mario Boccadoro,14 Antonio Palumbo,14 Bart Barlogie,15 Chaim Shustik,16 Michele Cavo,17 Philip R. Greipp,5 Douglas Joshua,18 Michel Attal,19 Pieter Sonneveld,20 and John Crowley3
منابع مشابه
CLINICAL TRIALS AND OBSERVATIONS Recent major improvement in long-term survival of younger patients with multiple myeloma
In the past, most patients with multiple myeloma (MM) died within 5 to 10 years after diagnosis. Within the past decade, several new therapeutic interventions have been introduced, including autologous stem-cell transplantation, thalidomide, lenalidomide, and bortezomib. We estimated trends in age-specific 5and 10-year relative survival of patients with MM in the United States from 1990-1992 to...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Racial disparities in incidence and outcome in multiple myeloma: a population-based study
Multiple myeloma (MM) is the most common hematologic malignancy in blacks. Some prior studies suggest inferior survival in blacks; others suggest similar survival. Using the original 9 Surveillance, Epidemiology, and End Results registries, we conducted a large-scale population-based study including 5798 black and 28 939 white MM patients diagnosed 1973-2005, followed through 2006. Age-adjusted...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma
Bortezomib, a potent and reversible proteasome inhibitor, affects the myeloma cell and its microenvironment, resulting in downregulation of growth and survival signaling pathways and durable responses in patients with relapsed and refractory myeloma. Potential associations between baseline parameters and outcomes with bortezomib were explored in 202 patients who received bortezomib 1.3 mg/m2 tw...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Improved survival in multiple myeloma and the impact of novel therapies
Treatments for myeloma have expanded in the last decade, but it is not clear if the introduction of novel therapies and the increased use of high-dose therapy have translated into better outcome for patients with myeloma. We examined the outcome of 2 groups of patients seen at a single institution, one from time of diagnosis and the other from the time of relapse, to examine the survival trends...
متن کاملMultidrug-resistant myeloma: laboratory and clinical effects of verapamil as a chemosensitizer.
Verapamil was evaluated as a chemosensitizer for reversing multidrug resistance in multiple myeloma both in vitro and in clinical trials. Bone marrows from 59 myeloma patients in relapse were evaluated for several resistance parameters: expression of p-glycoprotein (MDR1), doxorubicin (Adriamycin) and vincristine sensitivity, and the ability of added verapamil to reduce resistance to the cytoto...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره شماره
صفحات -
تاریخ انتشار 2008